Skip to search formSkip to main contentSkip to account menu

SCH-56592

Known as: SCH 56592 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

posaconazole

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis
Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis 
Review
2002
Review
2002
New agents for the treatment of systemic fungal infections – current status
Systemic antifungal chemotherapy is enjoying its most dynamic era. More antifungal agents are under development than ever before… 
2002
2002
In vitro and in vivo activity of SCH-56592 (Posaconazole) against aspergillus fumigatus
SCH 56592 (SCH) est un nouvel agent antifongique avec une puissante activite contre les champignons filamenteux. Materiel et… 
2002
2002
Activity of SCH-56592 against clinical isolates of Cryptococcus neoformans in-vivo and in-vitro
Objective:To investigate the in vitro and in vivo activity of SCH 56592, a new triazole antifungal agent, against clinical… 
Highly Cited
2001
Highly Cited
2001
Structural characterization of the oxidative degradation products of an antifungal agent SCH 56592 by LC-NMR and LC-MS.
2000
2000
High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum.
2000
2000
The antifungal agent SCH-56592 is effective in the treatment of experimental cutaneous leishmaniasis,
  • 2000
  • Corpus ID: 195134966
Highly Cited
1999
Highly Cited
1999
Efficacy of the Triazole SCH 56592 againstLeishmania amazonensis and Leishmania donovani in Experimental Murine Cutaneous and Visceral Leishmaniases
ABSTRACT Current therapy for leishmaniasis is unsatisfactory. Efficacious and safe oral therapy would be ideal. We examined the… 
1999
1999
Comparison of in vitro activity of two new triazoles, voriconazole and SCH-56592, and fluconazole against Candida albicans by time-kill methodology
1995
1995
New antifungal agents needed for immunocompromised patients
&Several pharmaceutical companies worldwide have joined in a race to develop new antifungal agents for patients with compromised… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)